Conceptualizing GLP-1R as a dynamic architect of spatiotemporally encoded signalosomes opens new avenues for a deeper understanding of incretin biology with the potential for identification of novel GLP-1R effectors and the development of refined therapeutic strategies for metabolic disease
GLP-1 drugs (also called GLP-1 agonists) are medications originally marketed to treat diabetes
Monthly persistency erosion is steeper in obesity: Obesity GLP-1s drop to 32% persistence over 13 months, compared to 41% for diabetes
Ntika S, Thombare K, Aryapoor M, Kristinsson H, Bergsten P, Krizhanovskii C
At research-level dosages, studies have not reported extensive adverse effects
Side effect sensitivity: Nausea, bloating, constipationthese can be tough to handle